

## Sheep Anti-h bcl-xl

**Product:** Sheep anti human bcl-xl antibody

**Description:** The immunogen for the sheep anti-human bcl-xl was a synthetic peptide corresponding to amino acids 3 to 14 of the human bcl-xl sequence. Overexpression of bcl-xl to other bcl-2 members is believed to promote cell survival. The ratio of bcl-xl to other family members is believed to modulate the apoptotic process.

**Background:** bcl-x is a bcl-2-related gene that can function as a regulator of programmed cell death (apoptosis) independent of bcl-2. Alternative splicing results in two distinct bcl-x mRNAs. The larger mRNA gives rise to a protein product, bcl-xl, which is similar in size and predicted structure to bcl-2 (1). The smaller mRNA gives rise to bcl-xS. bcl-x immunoreactivity has been detected in a wide variety of cell types and the protein is typically present in the cytosol in association with the mitochondrial periphery, a property shared with bcl-2 however membrane bound forms of bcl-x have been demonstrated in thymocytes (2-4). Following the induction of apoptosis all of the bcl-x protein shifts to the membrane form (2). Of the two isoforms of bcl-x, the long (bcl-xl) is the most abundant mRNA species expressed in embryonic and adult tissues and most likely differs from bcl-2 in its regulatory activity on cell differentiation through controlled tissue specific expression (1,3). Like its homolog bcl-2, bcl-x undergoes phosphorylation, a modification that requires that a specific 60 amino acid loop region be intact, which in turn appears to regulate activity (5,6). Structurally, based on 3D-structure analysis, bcl-x forms pH sensitive cation-selective ion channels in membranes a property shared with the pore forming domains of several bacterial toxins (7). Bcl-xl has been shown to modify the cell's response to oxidants, to participate in resistance to chemotherapeutic agents and radiation, and to play a key role in the development of the developing CNS (8-10).

**Isotype:** Sheep IgG

**Application:** Western Blot at 1-5 ug/ml. Positive control MCF-7 cells.

**Presentation:** 100 µg IgG purified from serum.

**Reactivity:** Reacts with human bcl-xl.

**Storage:** Antibodies should be stored at -20°C. Aliquot to avoid freeze/thaw cycles.

**Stability:** Antibodies are stable for one year from purchase if stored frozen.

<b>Ordering Information:</b>	<b>Form</b> Purified	<b>Vial Size</b> 100 µg	<b>Catalog #</b> A110P
------------------------------	-------------------------	----------------------------	---------------------------

### REFERENCES:

1. Boise L.H., et al. (1993) Cell 74: 597-608.
2. Krajewski S., et al. (1994) Cancer Res 54:5501-5507.
3. Gonzalez-Garcia M., et al. (1994) Development 120: 3033-3042.
4. Hsu, Y.T., et al. (1997) Proc. Natl. Acad. Sci USA 94: 3668-3672.

**For research use only. Not for use in human diagnostics or therapeutics.**

5. Benito, A., et al. (1997) *Leukemia* 11 940-944.
6. Chang, B.S., et al. (1997) *EMBO J.* 16: 968-977.
7. Minn, A.J., et al. (1997) *Nature* 385: 353-357.
8. Fang W., et al. (1995) *J Immunol* 155: 66-75.
9. Datta R., et al. (1995) *Cell Growth Differ* 6:363-370.
10. Shindler, K.S., et al. (1997) *J. Neurosci.* 17:3112-3119.

**For research use only. Not for use in human diagnostics or therapeutics.**

Exalpha Biologicals, Inc., 2 Shaker Rd, #B101, Shirley, MA 01464  
Tel: 800.395.1137 or 978.425.1370, Fax: 866.924.5100 or 978.425.1376, Web: [www.exalpha.com](http://www.exalpha.com)